A Phase 2 interventional study of Centanafadine and Placebo in Binge-Eating Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 25 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.
Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 28th largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2021, is one of 14 in phase 2, and was the 88th registered.
233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.
Browse Binge-Eating Disorder studies →20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:
Lindner Center of HOPE · Sites in United States
Ages up to 18
Trustees of Dartmouth College · Sites in United States
Ages 18–70
University of Kansas · Sites in United States
Ages 18–65
University of Oklahoma · Sites in United States
Ages 18–120
Milton S. Hershey Medical Center · Sites in United States
Ages 12–26
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 27 · Phase 3 25 · Phase 4 3
First in 1994; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 77 across 190 interventional studies indexed under Binge-Eating Disorder.
Median enrollment 67 across the 112 interventional studies, 224 across the 8 observational. Of the 89 that completed or were terminated, 34 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 122 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 1 study filed under Binge-Eating Disorder — fewer than ten, so there is no comparison to draw.
12 of the studies in Binge-Eating Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413433Phase 3Axsome Therapeutics, Inc.Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | 2026-12 |
| NCT06858774Icahn School of Medicine at Mount SinaiUse of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder | 2026-11 |
| NCT06485687Ali RezaiLow Intensity Focused Ultrasound for Binge Eating Disorder | 2026-12-31 |
| NCT05664516Massachusetts General HospitalA Study of the Effects of Oxytocin in Adults With Binge-eating Disorder | 2027-01 |
| NCT03393039University of California, San DiegoEffects of Negative Affect in Individuals With Binge Eating Episodes | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 122 studies in Binge-Eating Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy of 2 doses of centanafadine sustained-release (SR) (200 milligrams [mg] and 400 mg total daily dose [TDD]) compared with placebo in adults with moderate to severe binge eating disorder (BED).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive centanafadine 200 mg SR tablets, orally, twice daily (BID) at a TDD of 400 mg for 8 weeks.
Drug: Centanafadine
Participants will receive centanafadine 100 mg SR tablets, orally, BID at a TDD of 200 mg along with centanafadine matching placebo tablets, orally, BID for 8 weeks.
Drug: Centanafadine · Drug: Placebo
Participants will receive centanafadine matching placebo tablets, orally, BID for 8 weeks.
Drug: Placebo
Sustained-release oral tablets
Oral tablets
Change From Baseline in Number of Binge Eating Days Per Week
Binge eating day was defined as a day with at least one binge eating episode. Least squares (LS) mean was determined by Mixed-effect Model Repeated Measures (MMRM) method with change from baseline in binge eating days per week at scheduled visit as dependent variable and included fixed effect terms for treatment, trial center, visit week, and an interaction term of treatment by visit week.
Time frame: Baseline, Weeks 7 to 8
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score
The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on scale with a score range of 0 to 7 where, 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Time frame: Baseline, Week 8
Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) Related to Rash, AEs Related to Abuse, and AEs Involving Medication Handling Irregularities (MHIs)
An AE is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. AESIs were newly acquired skin eruptions that were non-traumatic which included eruptions such as skin rashes, skin irritations, skin reactions, or acneiform lesions. AEs related to abuse included: Feeling abnormal (floaty feeling in the head), euphoric mood (feeling high). MHIs included: IMP accounting errors, not involving suspected abuse nor diversion by participant; Non-compliance with trial procedures, not involving suspected abuse nor diversion by participant; and other cases involving neither suspected abuse nor diversion of trial IMP by participant.
Time frame: From first dose of study drug up to 1 week post last dose (Up to 9 weeks)
Number of Participants With Potentially Clinically Relevant Laboratory Abnormalities
Laboratory assessments included hematology, serum chemistry, and urinalysis. Abnormality criteria included: In milligrams per deciliter (mg/dL) \[high bilirubin ≥2.0, low/high calcium ≤8.2/ ≥12, high cholesterol fasting ≥240, high glucose, fasting ≥100, high triglycerides, fasting ≥150, high urate ≥8.5 female / ≥10.5 male, high protein urine ≥2 units increase\]; high creatine kinase (units per liter \[U/L\]) \>3xupper limit of normal (ULN); high eosinophils/leukocytes ≥10%, low neutrophils/leukocytes ≤15%; In 10\^3/microliter (µL) \[low or high leukocytes ≤2.8x10\^9/L or ≥16.0x10\^9/L, low neutrophils ≤1.5x10\^9/L\]. The categories with at least one participant with clinically relevant value are reported here.
Time frame: From first dose of study drug up to 1 week post last dose (Up to 9 weeks)
Number of Participants With Potentially Clinically Relevant Vital Sign Abnormalities
Vital sign measurements included heart rate in supine and standing positions (low: \<50 beats per minute \[bpm\] and decrease ≥10 bpm; High: \>100 bpm and increase ≥10 bpm), systolic blood pressure (BP) in supine and standing positions (low: \<90 millimeters of mercury \[mmHg\] and decrease ≥20 mmHg; High: ≥140 mmHg and increase ≥20 mmHg), diastolic BP in supine and standing positions (low: \<60 mmHg and decrease ≥10 mmHg; High: ≥90 mmHg and increase ≥10 mmHg), weight in kilograms (kg) (low: ≥7% decrease; High: ≥7% increase), orthostatic hypotension, (≥30mmHg decrease is systolic BP or ≥20 mmHg in diastolic BP after at least 3 minutes of standing compared to the previous supine BP), and orthostatic tachycardia (≥25 bpm increase in heart rate from supine to standing). The categories with at least one participant with clinically relevant value are reported here.
Time frame: From first dose of study drug up to 1 week post last dose (Up to 9 weeks)
Number of Participants With Potentially Clinically Relevant 12-Lead Electrocardiogram (ECG) Abnormalities
12-lead ECG abnormality criteria included Rhythm: Supraventricular premature beat (not present at baseline and present post baseline); and Conduction: Primary (1°) atrioventricular block (PR ≥200 milliseconds \[msec\] and increase of ≥50 msec).
Time frame: From first dose of study drug up to 1 week post last dose (Up to 9 weeks)
Study Medication Withdrawal Questionnaire (SMWQ) Total Mean Score
SMWQ is a questionnaire to assess withdrawal symptoms subsequent to completion of dosing with IMP. The SMWQ is a modification of the Amphetamine Withdrawal Questionnaire, in which in which the terms "amphetamines and methamphetamine" are replaced with the term "the study medication." This change was intended to prevent bias by implying that the trial medication might be an amphetamine or amphetamine-like stimulant when presented with the survey. This questionnaire comprises of 13 items which describe symptoms associated with the cessation of study medication use for which participants indicate severity on a scale with scores ranging from 0 (no withdrawal symptoms) to 4 (most severe withdrawal symptom). The total score is calculated as the sum of all the scores for the 13 items, ranging from 0 to 52. Lower scores indicate less withdrawal symptoms.
Time frame: Week 8
Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score
The HAM-A scale assesses both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It consists of 14 items to rate the severity of symptoms of anxiety, each scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Total score was calculated as the sum of the 14 individual item scores, ranging from 0 to 56 and categorized as 0-13: normal range, 14-17: mild severity, 18-24: mild to moderate severity, 25-30: moderate to severe, and \>=31: severe. A higher score indicates a more severe anxiety.
Time frame: Baseline, Week 8
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a diagnostic questionnaire used by clinician to assess the participant's severity of depression. The questionnaire includes questions on ten symptoms: Apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, difficulty concentrating, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each question is scored on a range of 0 to 6 points and the total score was calculated as the sum of the 10 individual item scores, ranging from 0 to 60 categorized as: 0 to 6: normal/symptoms absent, 7 to 19: mild depression, 20 to 34: moderate depression, and 35 to 60: severe depression. Higher scores indicate increased depressive symptoms.
Time frame: Baseline, Week 8
Number of Participants With Suicidality as Measured by Columbia Suicide Severity Rating Scale (C-SSRS) Score
The C-SSRS is a clinician-administered instrument that systematically assess suicidal ideation (SI) and suicidal behavior rating scale. It rates an individual's degree of SI on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent). The scale identifies specific behaviors ranging from "preparatory acts or behavior" to "suicide" which may be indicative of an individual's intent to complete suicide. Suicidality was reported in this outcome measure, defined as at least 1 occurrence of suicidal ideation or at least 1 occurrence of suicidal behavior for each assessment period.
Time frame: Week 8
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score
The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on scale with a score range of 0 to 7 where, 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Time frame: Baseline, Weeks 1, 2, 3, 4, and 6
Mean Clinical Global Impression - Change (CGI-C) Score
The CGI-C is a single-item, 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to their baseline state at the beginning of treatment, rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. A higher score on the CGI-C represents a greater disease progression.
Time frame: Week 8
Change From Baseline in Yale-Brown Obsessive-Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Score
The Y-BOCS-BE is a clinician-rated scale that assesses obsession with binge eating thoughts and compulsiveness of binge eating behaviors. The Y-BOCS-BE is a 10-item scale, divided into 2 subscales with 5 items each: obsessions and compulsions. Each item is rated from 0 (no symptoms) to 4 (extreme symptoms) and total scores range from 0 to 40. A score of 0 to 7 is considered sub-clinical; 8 to 15 as mild; 16 to 23 as moderate; 24 to 31 as severe; and 32 to 40 as extreme obsession and compulsiveness of binge eating. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Time frame: Baseline, Week 8
Percentage of Participants With Four-Week Cessation From Binging
Percentages are rounded off to the nearest single decimal point.
Time frame: Week 8
Change From Baseline in Number of Binge Episodes Per Week
All binge eating episodes were recorded daily by the participant in a binge eating diary. At each visit, the investigator reviewed the completed diary and assessed the number of binges for each day. Number of binge episodes per week are reported. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Time frame: Baseline, Weeks 7 to 8
Change From Baseline in Patient Global Impression - Severity (PGI-S) Score
The PGI-S is a single-item self-report of the participant's severity of symptoms. Severity is rated on a 7-point scale: 1 = no symptoms; 2 = minimal; 3 = mild; 4 = moderate; 5 = marked; 6 = severe; 7 = very severe. A higher score indicates more severe symptoms. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Time frame: Baseline, Week 8
Mean Patient Global Impression - Change (PGI-C) Score
The PGI-C is a single-item, self-report that requires the participant to assess how much his/her illness has improved or worsened relative to baseline and rate on a 7-point scale: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. A higher score indicates a greater disease progression.
Time frame: Week 8
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2): Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
The SF-36 is a health-related survey that assesses participant's health status and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health, mental health, social functioning, and vitality. The 8 domains are combined to form 2 component scores: PCS and MCS. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health-related quality of life. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Time frame: Baseline, Week 8
Change From Baseline in Eating Disorder Examination Questionnaire-7-Item Version (EDE-Q7) Total Score
The EDE-Q7 is a self-report version of the eating disorder examination (EDE) and measures eating-disorder psychopathology in the past 28 days and over longer intervals. It comprises of 3 subscale scores (dietary restraint, shape/weight overvaluation, and body dissatisfaction). An EDE-Q global (total) score is calculated as average of 3 subscale scores and ranges from 0 (absence of the feature) to 6 (extreme degree). A higher score indicates a more severe outcome. LS mean was determined by ANCOVA model with treatment and trial center as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 8
Participants took part in this study at investigational sites in the United States from 22 December 2021 to 19 August 2022.
| Milestone | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Started | 49 | 49 | 49 |
| Safety analysis set | 49 | 49 | 49 |
| Efficacy analysis set | 49 | 48 | 47 |
| Completed | 36 | 39 | 40 |
| Not completed | 13 | 10 | 9 |
| Withdrew: Adverse event | 5 | 0 | 3 |
| Withdrew: Lost to follow-up | 3 | 4 | 2 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 6 | 4 |
| Withdrew: Reason not specified | 2 | 0 | 0 |
Binge eating day was defined as a day with at least one binge eating episode. Least squares (LS) mean was determined by Mixed-effect Model Repeated Measures (MMRM) method with change from baseline in binge eating days per week at scheduled visit as dependent variable and included fixed effect terms for treatment, trial center, visit week, and an interaction term of treatment by visit week.
| binge eating days per week | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Number of Binge Eating Days Per Week | -3.44 ± 0.23 | -3.07 ± 0.23 | -3.01 ± 0.23 |
The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on scale with a score range of 0 to 7 where, 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
| score on a scale | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score | -2.15 ± 0.18 | -1.43 ± 0.18 | -1.61 ± 0.18 |
The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on scale with a score range of 0 to 7 where, 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Results for this outcome have not been posted.
The CGI-C is a single-item, 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to their baseline state at the beginning of treatment, rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. A higher score on the CGI-C represents a greater disease progression.
Results for this outcome have not been posted.
The Y-BOCS-BE is a clinician-rated scale that assesses obsession with binge eating thoughts and compulsiveness of binge eating behaviors. The Y-BOCS-BE is a 10-item scale, divided into 2 subscales with 5 items each: obsessions and compulsions. Each item is rated from 0 (no symptoms) to 4 (extreme symptoms) and total scores range from 0 to 40. A score of 0 to 7 is considered sub-clinical; 8 to 15 as mild; 16 to 23 as moderate; 24 to 31 as severe; and 32 to 40 as extreme obsession and compulsiveness of binge eating. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Results for this outcome have not been posted.
Percentages are rounded off to the nearest single decimal point.
Results for this outcome have not been posted.
All binge eating episodes were recorded daily by the participant in a binge eating diary. At each visit, the investigator reviewed the completed diary and assessed the number of binges for each day. Number of binge episodes per week are reported. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Results for this outcome have not been posted.
The PGI-S is a single-item self-report of the participant's severity of symptoms. Severity is rated on a 7-point scale: 1 = no symptoms; 2 = minimal; 3 = mild; 4 = moderate; 5 = marked; 6 = severe; 7 = very severe. A higher score indicates more severe symptoms. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Results for this outcome have not been posted.
The PGI-C is a single-item, self-report that requires the participant to assess how much his/her illness has improved or worsened relative to baseline and rate on a 7-point scale: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. A higher score indicates a greater disease progression.
Results for this outcome have not been posted.
The SF-36 is a health-related survey that assesses participant's health status and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health, mental health, social functioning, and vitality. The 8 domains are combined to form 2 component scores: PCS and MCS. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health-related quality of life. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.
Results for this outcome have not been posted.
The EDE-Q7 is a self-report version of the eating disorder examination (EDE) and measures eating-disorder psychopathology in the past 28 days and over longer intervals. It comprises of 3 subscale scores (dietary restraint, shape/weight overvaluation, and body dissatisfaction). An EDE-Q global (total) score is calculated as average of 3 subscale scores and ranges from 0 (absence of the feature) to 6 (extreme degree). A higher score indicates a more severe outcome. LS mean was determined by ANCOVA model with treatment and trial center as fixed factors and baseline value as covariate.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. AESIs were newly acquired skin eruptions that were non-traumatic which included eruptions such as skin rashes, skin irritations, skin reactions, or acneiform lesions. AEs related to abuse included: Feeling abnormal (floaty feeling in the head), euphoric mood (feeling high). MHIs included: IMP accounting errors, not involving suspected abuse nor diversion by participant; Non-compliance with trial procedures, not involving suspected abuse nor diversion by participant; and other cases involving neither suspected abuse nor diversion of trial IMP by participant.
| Participants | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| AEs | 34 | 28 | 24 |
| AESIs Related to Rash | 5 | 3 | 1 |
| AEs Related to Abuse | 2 | 1 | 0 |
| AEs Involving MHIs | 2 | 2 | 3 |
Laboratory assessments included hematology, serum chemistry, and urinalysis. Abnormality criteria included: In milligrams per deciliter (mg/dL) \[high bilirubin ≥2.0, low/high calcium ≤8.2/ ≥12, high cholesterol fasting ≥240, high glucose, fasting ≥100, high triglycerides, fasting ≥150, high urate ≥8.5 female / ≥10.5 male, high protein urine ≥2 units increase\]; high creatine kinase (units per liter \[U/L\]) \>3xupper limit of normal (ULN); high eosinophils/leukocytes ≥10%, low neutrophils/leukocytes ≤15%; In 10\^3/microliter (µL) \[low or high leukocytes ≤2.8x10\^9/L or ≥16.0x10\^9/L, low neutrophils ≤1.5x10\^9/L\]. The categories with at least one participant with clinically relevant value are reported here.
| Participants | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| High Bilirubin (mg/dL) | 0 | 0 | 1 |
| Low Calcium (mg/dL) | 0 | 1 | 0 |
| High Cholesterol, Fasting (mg/dL) | 8 | 6 | 4 |
| High Creatine Kinase (U/L) | 2 | 1 | 1 |
| High Glucose, Fasting (mg/dL) | 7 | 11 | 8 |
| High Triglycerides, Fasting (mg/dL) | 6 | 9 | 14 |
| High Urate: Males and Females (mg/dL) | 0 | 1 | 0 |
| High Eosinophils/Leukocytes (%) | 2 | 4 | 3 |
| Low Leukocytes (10^3/µL) | 2 | 2 | 2 |
| Low Neutrophils (10^3/µL) | 8 | 6 | 3 |
| Low Neutrophils/Leukocytes (%) | 3 | 2 | 2 |
| High Protein, Urine (mg/dL) | 18 | 15 | 14 |
Vital sign measurements included heart rate in supine and standing positions (low: \<50 beats per minute \[bpm\] and decrease ≥10 bpm; High: \>100 bpm and increase ≥10 bpm), systolic blood pressure (BP) in supine and standing positions (low: \<90 millimeters of mercury \[mmHg\] and decrease ≥20 mmHg; High: ≥140 mmHg and increase ≥20 mmHg), diastolic BP in supine and standing positions (low: \<60 mmHg and decrease ≥10 mmHg; High: ≥90 mmHg and increase ≥10 mmHg), weight in kilograms (kg) (low: ≥7% decrease; High: ≥7% increase), orthostatic hypotension, (≥30mmHg decrease is systolic BP or ≥20 mmHg in diastolic BP after at least 3 minutes of standing compared to the previous supine BP), and orthostatic tachycardia (≥25 bpm increase in heart rate from supine to standing). The categories with at least one participant with clinically relevant value are reported here.
| Participants | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Low Heart Rate Supine (bpm) | 1 | 0 | 0 |
| High Heart Rate Supine (bpm) | 0 | 1 | 3 |
| High Systolic BP Supine (mmHg) | 5 | 1 | 3 |
| Low Diastolic BP Supine (mmHg) | 1 | 2 | 0 |
| High Diastolic BP Supine (mmHg) | 6 | 1 | 3 |
| High Heart Rate Standing (bpm) | 6 | 4 | 6 |
| Low Systolic BP Standing (mmHg) | 1 | 0 | 0 |
| High Systolic BP Standing (mmHg) | 3 | 2 | 4 |
| Low Diastolic BP Standing (mmHg) | 1 | 1 | 0 |
| High Diastolic BP Standing (mmHg) | 10 | 3 | 6 |
| Low Weight (kg) | 3 | 1 | 1 |
| High Weight (kg) | 0 | 1 | 0 |
| Orthostatic Hypotension (mmHg) | 2 | 3 | 1 |
| Orthostatic Tachycardia (mmHg) | 8 | 5 | 4 |
12-lead ECG abnormality criteria included Rhythm: Supraventricular premature beat (not present at baseline and present post baseline); and Conduction: Primary (1°) atrioventricular block (PR ≥200 milliseconds \[msec\] and increase of ≥50 msec).
| Participants | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Supraventricular Premature Beat | 0 | 1 | 0 |
| 1° Atrioventricular Block | 0 | 0 | 1 |
SMWQ is a questionnaire to assess withdrawal symptoms subsequent to completion of dosing with IMP. The SMWQ is a modification of the Amphetamine Withdrawal Questionnaire, in which in which the terms "amphetamines and methamphetamine" are replaced with the term "the study medication." This change was intended to prevent bias by implying that the trial medication might be an amphetamine or amphetamine-like stimulant when presented with the survey. This questionnaire comprises of 13 items which describe symptoms associated with the cessation of study medication use for which participants indicate severity on a scale with scores ranging from 0 (no withdrawal symptoms) to 4 (most severe withdrawal symptom). The total score is calculated as the sum of all the scores for the 13 items, ranging from 0 to 52. Lower scores indicate less withdrawal symptoms.
| score on a scale | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Study Medication Withdrawal Questionnaire (SMWQ) Total Mean Score | 5.56 ± 4.80 | 7.72 ± 6.59 | 6.40 ± 6.47 |
The HAM-A scale assesses both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It consists of 14 items to rate the severity of symptoms of anxiety, each scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Total score was calculated as the sum of the 14 individual item scores, ranging from 0 to 56 and categorized as 0-13: normal range, 14-17: mild severity, 18-24: mild to moderate severity, 25-30: moderate to severe, and \>=31: severe. A higher score indicates a more severe anxiety.
| score on a scale | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score | -1.23 ± 3.76 | 0.55 ± 4.80 | -1.20 ± 4.22 |
The MADRS is a diagnostic questionnaire used by clinician to assess the participant's severity of depression. The questionnaire includes questions on ten symptoms: Apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, difficulty concentrating, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each question is scored on a range of 0 to 6 points and the total score was calculated as the sum of the 10 individual item scores, ranging from 0 to 60 categorized as: 0 to 6: normal/symptoms absent, 7 to 19: mild depression, 20 to 34: moderate depression, and 35 to 60: severe depression. Higher scores indicate increased depressive symptoms.
| score on a scale | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -0.20 ± 4.15 | 0.00 ± 6.56 | -1.20 ± 4.60 |
The C-SSRS is a clinician-administered instrument that systematically assess suicidal ideation (SI) and suicidal behavior rating scale. It rates an individual's degree of SI on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent). The scale identifies specific behaviors ranging from "preparatory acts or behavior" to "suicide" which may be indicative of an individual's intent to complete suicide. Suicidality was reported in this outcome measure, defined as at least 1 occurrence of suicidal ideation or at least 1 occurrence of suicidal behavior for each assessment period.
| Participants | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| Number of Participants With Suicidality as Measured by Columbia Suicide Severity Rating Scale (C-SSRS) Score | 0 | 1 | 0 |
Collected over From first dose of study drug up to 1 week post last dose (Up to 9 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Centanafadine 400 mg | 0/49 (0%) | 0/49 (0%) | 20/49 (40.8%) |
| Centanafadine 200 mg | 0/49 (0%) | 0/49 (0%) | 12/49 (24.5%) |
| Placebo | 0/49 (0%) | 0/49 (0%) | 11/49 (22.4%) |
| Event | Centanafadine 400 mg | Centanafadine 200 mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 2/49 | 7/49 | 2/49 |
| DiarrhoeaGastrointestinal disorders | 5/49 | 3/49 | 4/49 |
| NauseaGastrointestinal disorders | 5/49 | 1/49 | 3/49 |
| Dry MouthGastrointestinal disorders | 4/49 | 2/49 | 1/49 |
| ConstipationGastrointestinal disorders | 3/49 | 2/49 | 0/49 |
| InsomniaPsychiatric disorders | 3/49 | 2/49 | 1/49 |
| RashSkin and subcutaneous tissue disorders | 3/49 | 3/49 | 1/49 |
Randomized analysis set included all participants who were randomized in the double-blind treatment period.
| Age, Continuous(years) | Centanafadine 400 mg | Centanafadine 200 mg | Placebo | Total |
|---|---|---|---|---|
| Age | 42.5 ± 11.4 | 43.3 ± 11.1 | 45.6 ± 11.0 | 43.8 ± 11.2 |
| Sex: Female, Male(Participants) | Centanafadine 400 mg | Centanafadine 200 mg | Placebo | Total |
|---|---|---|---|---|
| Sex — Female | 41 | 41 | 41 | 123 |
| Sex — Male | 8 | 8 | 8 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Centanafadine 400 mg | Centanafadine 200 mg | Placebo | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 10 | 4 | 4 | 18 |
| Ethnicity — Not Hispanic or Latino | 39 | 45 | 45 | 129 |
| Ethnicity — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Centanafadine 400 mg | Centanafadine 200 mg | Placebo | Total |
|---|---|---|---|---|
| Race — White | 40 | 32 | 37 | 109 |
| Race — Black or African American | 5 | 11 | 9 | 25 |
| Race — American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Race — Asian | 2 | 4 | 2 | 8 |
| Race — Other | 2 | 1 | 1 | 4 |
| Binge Eating Days Per Week(binge eating days per week) | Centanafadine 400 mg | Centanafadine 200 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 4.43 ± 1.21 | 4.56 ± 1.07 | 4.56 ± 1.06 | 4.5 ± 1.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Dec 2021 to primary completion in Aug 2022, 7 months.
Results were first posted in Sep 2025, 3 years after primary completion. A results delay was requested in Aug 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Centanafadine
Otsuka Pharmaceutical Development & Commercialization, Inc. →